S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)

Cytokinetics (CYTK) Stock Forecast, Price & News

$29.92
-0.08 (-0.27%)
(As of 05:18 PM ET)
Compare
Today's Range
$29.71
$30.55
50-Day Range
$29.98
$36.61
52-Week Range
$29.71
$52.40
Volume
706,437 shs
Average Volume
885,535 shs
Market Capitalization
$2.87 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$58.21

Cytokinetics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.93 Rating Score
Upside/​Downside
95.3% Upside
$58.21 Price Target
Short Interest
Bearish
13.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.53
Upright™ Environmental Score
News Sentiment
0.60mentions of Cytokinetics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$2.96 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.10) to ($3.81) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

288th out of 963 stocks

Pharmaceutical Preparations Industry

118th out of 451 stocks


CYTK stock logo

About Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

CYTK Price History

CYTK Stock News Headlines

Cytokinetics: Clinical Efficacy Isn't Enough For Success
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Truist Financial Sticks to Their Buy Rating for Cytokinetics (CYTK)
Mizuho Securities Sticks to Its Buy Rating for Cytokinetics (CYTK)
Cytokinetics (CYTK) Receives a Buy from Mizuho Securities
Aficamten Sets Cytokinetics Apart In Cardiomyopathy
Piper Sandler Remains a Buy on Cytokinetics (CYTK)
H.C. Wainwright Keeps Their Buy Rating on Cytokinetics (CYTK)
11 Analysts Have This to Say About Cytokinetics
See More Headlines
Receive CYTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

CYTK Company Calendar

Last Earnings
8/03/2023
Today
9/27/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYTK
Employees
409
Year Founded
1997

Price Target and Rating

Average Stock Price Forecast
$58.21
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$42.00
Forecasted Upside/Downside
+95.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.93
Research Coverage
14 Analysts

Profitability

Net Income
$-388,950,000.00
Net Margins
-5,419.17%
Pretax Margin
-5,422.19%

Debt

Sales & Book Value

Annual Sales
$94.59 million
Book Value
($1.14) per share

Miscellaneous

Free Float
92,350,000
Market Cap
$2.86 billion
Optionable
Optionable
Beta
0.74

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Robert I. BlumMr. Robert I. Blum (Age 59)
    CEO, Pres & Director
    Comp: $1.14M
  • Mr. Ching W. JawMr. Ching W. Jaw (Age 60)
    Sr. VP & CFO
    Comp: $698.49k
  • Mr. Robert C. Wong (Age 55)
    VP & Chief Accounting Officer
    Comp: $463.75k
  • Dr. Fady Ibraham Malik FACC (Age 59)
    M.D., Ph.D., Exec. VP of R&D
    Comp: $776.99k
  • Mr. Andrew M. Callos (Age 67)
    Exec. VP & Chief Commercial Officer
    Comp: $745.4k
  • Dr. James A. Spudich Ph.D. (Age 81)
    Co-Founder & Member of Scientific Advisory Board
  • Mr. Jeff Lotz
    VP of Sales & Operations
  • Mr. Steven M. Cook (Age 64)
    Sr. VP of Supply Chain Operations & Technical Operations
  • Ms. Diane Weiser
    Sr. VP of Corp. Communications & Investor Relations
  • Ms. Kari K. Loeser J.D.
    VP & Chief Compliance Officer













CYTK Stock - Frequently Asked Questions

Should I buy or sell Cytokinetics stock right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last twelve months. There are currently 1 hold rating and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CYTK shares.
View CYTK analyst ratings
or view top-rated stocks.

What is Cytokinetics' stock price forecast for 2023?

14 brokerages have issued 12 month price targets for Cytokinetics' shares. Their CYTK share price forecasts range from $42.00 to $80.00. On average, they predict the company's stock price to reach $58.21 in the next twelve months. This suggests a possible upside of 95.2% from the stock's current price.
View analysts price targets for CYTK
or view top-rated stocks among Wall Street analysts.

How have CYTK shares performed in 2023?

Cytokinetics' stock was trading at $45.82 at the beginning of the year. Since then, CYTK stock has decreased by 34.9% and is now trading at $29.83.
View the best growth stocks for 2023 here
.

Are investors shorting Cytokinetics?

Cytokinetics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 12,550,000 shares, an increase of 8.1% from the August 31st total of 11,610,000 shares. Based on an average daily trading volume, of 799,100 shares, the short-interest ratio is presently 15.7 days. Approximately 13.7% of the shares of the stock are short sold.
View Cytokinetics' Short Interest
.

When is Cytokinetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our CYTK earnings forecast
.

How were Cytokinetics' earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) posted its quarterly earnings results on Thursday, August, 3rd. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing analysts' consensus estimates of ($1.23) by $0.11. The biopharmaceutical company had revenue of $0.87 million for the quarter, compared to analysts' expectations of $5.67 million. Cytokinetics had a negative trailing twelve-month return on equity of 1,401.63% and a negative net margin of 5,419.17%. The company's revenue was down 99.0% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.23) earnings per share.

What is Robert I. Blum's approval rating as Cytokinetics' CEO?

16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees.

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (16.00%), State Street Corp (5.30%), Polar Capital Holdings Plc (2.77%), Geode Capital Management LLC (1.99%), Artal Group S.A. (1.48%) and Bank of New York Mellon Corp (1.35%). Insiders that own company stock include B Lynne Parshall, Bvf Partners L P/Il, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, John T Henderson, L Patrick Gage, Mark A Schlossberg, Muna Bhanji, Robert I Blum, Robert I Blum, Robert Wong, Sandford D Smith, Sandford D Smith, Santo J Costa and Wendall Wierenga.
View institutional ownership trends
.

How do I buy shares of Cytokinetics?

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $29.83.

How much money does Cytokinetics make?

Cytokinetics (NASDAQ:CYTK) has a market capitalization of $2.86 billion and generates $94.59 million in revenue each year. The biopharmaceutical company earns $-388,950,000.00 in net income (profit) each year or ($5.69) on an earnings per share basis.

How many employees does Cytokinetics have?

The company employs 409 workers across the globe.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytokinetics.com. The biopharmaceutical company can be reached via phone at (650) 624-3000, via email at investor@cytokinetics.com, or via fax at 650-624-3010.

This page (NASDAQ:CYTK) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -